Takeda Pharmaceuticals continues its slimming program, and multinational pharmaceutical companies are restructuring and laying off workers.

Guide: Takeda Pharmaceuticals recruits early retirees in Japan for employees over the age of 30.
, Takeda announced that it would recruit early retirement workers in Japan's domestic departments between September 28 and October 16.
the recruitment is aimed primarily at the sales and administration departments and does not apply to the research and development and manufacturing departments, and employees who have worked continuously for more than 3 years and are over 30 years of age can apply, but the exact number of recruits has not been made public.
said the move was part of a personnel reform taken by Takeda Pharmaceuticals for the future.
that for early retirement employees, Takeda Pharmaceuticals will support their re-employment in addition to paying a specially weighted pension.
first announced its acquisition of Shire in 2018, Mr Takeda said it would cut 6 to 7 per cent of its annual cost-cutting target of $1.4bn.
, the company recently raised its target to $2.3 billion.
wants to cut back on pharmaceutical representatives selling drugs to doctors and hospitals and rely more on contract sellers to increase flexibility, according to people familiar with the matter.
, Japan's major pharmaceutical companies have also scaled back their sales forces in response to shrinking markets and lower drug prices in the nhs.
s $59 billion acquisition of Shire last year triggered a company-wide restructuring by buying Shire for $59 billion.
is seeking to divest $10bn of non-core assets to reduce the $48bn in debt required to acquire Shire.
, Takeda has been selling non-core assets since 2019 to make sweeping changes.
Tooka announced in May 2019 that it would sell TachoSil to Johnson and Johnson subsidiary Ethicon for $400 million, and in July 2019 it sold Xiidra, a new dry-eye drug owned by Shire, to Novartis for $5.3 billion. Announced in October 2019 the transfer of rights to approximately 30 over-the-counter and prescription drugs to Acino in the Middle East and Africa markets for more than $200 million, and in November 2019 announced the sale of non-core portfolios in Russia, Georgia and several CIS countries to STADA for $660 million.
2020, Takeda reached an agreement with Hypera S.A. of Brazil to sell 18 brands of prescription and consumer health drugs in the Latin American market for $825 million.
, Takeda Pharmaceuticals is rumoured to be selling its over-the-counter drug subsidiary Takeda Consumer Health to Blackstone for 15.8 billion yuan.
's goal is to get 31 new drug approvals in Japan by 2024, including new molecules and brands that have already been approved for market outside Japan.
will focus on five business areas in Japan, namely gastrointestinal, rare diseases, oncology, neuroscience and plasma therapy.
and reform its human resources system to change Japan's typical life-long employment system.
, Takeda transferred 170 medical representatives from primary care to oncology in April and 50 to the Department of Neuroscience.
also said it would continue to adjust its structure as new products were introduced and product lines progressed.
, the restructuring and transformation of large pharmaceutical enterprises in recent years more and more multinational pharmaceutical companies began to play the "return to the core business" slogan.
Since 2018, Takeda, Bayer, Pfizer, GSK, Mercer and other multinational pharmaceutical companies, have split, divestiture, shut down pipelines, and even large-scale layoffs and other "big-money" adjustments, and since 2020, the trend has continued unabated.
first to announce a split plan in the first half of 2020 was Mercer East.
February, Mercer announced that it would begin divesting its women's health products, mature products and biosimilar products in 2020 to form a new independent public company.
will retain cancer, vaccines, in-hospital products and animal health products, which are key growth points.
and Mercer east announced the split almost simultaneously, GSK.
February 5, GSK announced a two-year spin-off that will split into two separate companies, a biopharmaceutical company focused on gene and new technologies for immune system-related science and a leading company in consumer health.
August 3rd, Bayer completed the sale of bayer animal health to U.S. company Lilan.
from the above can be clearly seen, large pharmaceutical companies to lay off staff or adjust the product line, the root cause is to reduce costs, while cutting jobs while changing blood.
position by continuing to focus on the company's key business and innovative drug channels.
These multinational pharmaceutical companies between the reorganization, separation, will inevitably affect the global pharmaceutical pattern, correspondingly, multinational pharmaceutical companies will continue to more frequent strategic adjustment period, personnel changes, acquisitions, mergers and acquisitions, sales of business will become the norm.
source: 1. Takeda Offers Japanese Sales, admin staffers early retirement in post-Shire slimdown2. Tak. US) $15.8 billion sale of over-the-counter drug subsidiary to Blackstone Group (BX. US) 3. Takeda agreed to pay Hypera Pharma $825 million for part of Latin America over-the-counter.